Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials.
David L WirtaMichael S KorenfeldShane FosterRobert Smyth-MedinaJason BacharachShane R KannarrMark J JarosCharles B SlonimPublished in: Clinical ophthalmology (Auckland, N.Z.) (2021)
Once-daily oxymetazoline 0.1% was safe and well tolerated in participants with acquired blepharoptosis when used for 14-84 days. Safety did not appear to differ based on age, race, or ethnicity.